A key late-stage clinical trial of Gilead Sciences, Inc.’s Trodelvy (sacituzumab govitecan-hziy) failed, causing the company’s stock to drop and raising questions among analysts about its position relative to its competitor, AstraZeneca PLC/Daiichi Sankyo Co., Ltd.’s datopotamab deruxtecan (dato-DXd). But the results were not seen as entirely negative, given that EVOKE-01 was in a difficult population where dato-DXd has also seen lackluster results.
Do The Dark Clouds Over Gilead’s Trodelvy Have A Silver Lining?
Despite a primary endpoint miss in previously treated NSCLC in EVOKE-01, analysts say the drug still has points of differentiation from the competition.
More from Clinical Trials
More from R&D
• By
AstraZeneca remains committed to investing in R&D and alliances in China, where Susan Galbraith, the UK major’s head of oncology R&D, sees innovation eventually reaching parity with the US and Europe.
• By
BeiGene’s Phase III ociperlimab joins the list of failed TIGIT inhibitors, as candidates from Roche, Merck & Co. and others have failed late-stage studies.
• By
With new Phase II data, Edgewise asserted that EDG-7500, a sarcomere modulator, could offer better efficacy and safety than cardiac myosin inhibitors in hypertrophic cardiomyopathy.